Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (244)	4/22/2003 5:11:03 PM
From: Biomaven	Read Replies (2) \| Respond to of 4232

Maurice, On the other hand, today we can put you on a respirator and sometimes you even successfully come off a respirator. So there would be some offsetting gains to go with your more vulnerable population. The SARS mortality might actually be quite different from 7%. Earlier today I posted the figures of deaths:recoveries - this was much higher - more like 20%. That figure will likely change, and of course it is only for people sick enough to be diagnosed to begin with - we just have no idea whether there are a bunch of not-very-sick SARS patients out there who think they just have a cold. (In other words the 5-7% mortality rate currently being publicized assumes that everyone currently still sick will recover). [Edit: - I see you posted on this issue earlier. It's not really an upper limit though - what happens if everyone still sick were to die?] Peter